Opioid Dependence

Primary Care - Clinics in Office Practice

Volumn 38, Issue 1, 2011, Pages 59-70

  Benich, Joseph J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Buprenorphine; Dependence; Detoxification; Methadone; Opioid; Withdrawal

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; BUPRENORPHINE; CLONIDINE; LOFEXIDINE; METHADONE; MUSCLE RELAXANT AGENT; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PLACEBO; TRAZODONE;

CLINICAL FEATURE; CONSTIPATION; DIAPHORESIS; DIARRHEA; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERANCE; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; HUMAN; HYPERTENSION; LIBIDO; LOW DRUG DOSE; MAINTENANCE THERAPY; MUSCLE SPASM; NAUSEA; NEUROBIOLOGY; NEUROMODULATION; OPIATE ADDICTION; PAIN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SOCIAL PROBLEM; SOMNOLENCE; TOBACCO DEPENDENCE; TORSADE DES POINTES; URINE RETENTION; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; BEHAVIOR THERAPY; BUPRENORPHINE; COGNITIVE THERAPY; HUMANS; METHADONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PSYCHOTHERAPY; SUBSTANCE WITHDRAWAL SYNDROME; UNITED STATES;

EID: 79951995616     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2010.11.005     Document Type: Review

References (58)

1. Donaher P.A., Welsh C. Managing opioid addiction with buprenorphine. Am Fam Physician 2006, 73(9):1573-1578.
2. Krambeer L.L., Von McKnelly W., Gabrielli, et al. Methadone therapy for opioid dependence. Am Fam Physician 2001, 63:2404-2410.
3. Brooner R.K., King V.L., Kidorf M., et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997, 54:71-80.
4. Strain E.C. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain 2002, 18:514-527.
5. Van de Brink W., Haasen C. Evidence-based treatment of opioid-dependent patients. Canada Journal of Psychiatry 2006, 51:635-646.
6. Haug N.A., Sorensen J.L., Gruber V.A., et al. Relapse prevention for opioid dependence. Relapse prevention: maintenance strategies in the treatment of addictive behaviors 2005, 151-178. Guilford Press, New York. 2nd edition. G.A. Mariatt, D.M. Donovan (Eds.).
7. Mark T.L., Woody G.E., Juday T., et al. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001, 61:195-206.
8. Substance abuse and mental health services administration. Treatment episode data set Available at:, Accessed February 2, 2010. http://www.oas.samhsa.gov/TEDS2k7highlights/TEDSHighl2k7Tbl4.htm.
9. Hayward M.D., Schaich-Borg A., Pintar J.E., et al. Differential involvement of endogenous opioids in sucrose consumption and food reinforcement. Pharmacol Biochem Behav 2006, 85:601-611.
10. Shippenberg T.S., Chefer V.I., Thompson A.C. Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine. Biol Psychiatry 2009, 65(2):169-174.
11. Jaffe J.H., Martin W.R. Opioid analgesics and antagonists. Goodman and Gilman's the pharmacological basis of therapeutics 1990, 485-521. Pergamon Press, New York. 8th edition. A.G. Gilman, T.W. Rall, A.S. Nies (Eds.).
12. Marshall B.E., Longnecker D.E. General anesthetics. Goodman and Gilman's the pharmacological basis of therapeutics 1990, 311-331. Pergamon Press, New York. 8th edition. A.G. Gilman, T.W. Rall, A.S. Nies (Eds.).
13. Jaffe J.H. Opiates: clinical aspects. Substance abuse a comprehensive textbook 1992, 186-193. Williams and Wilkins, Baltimore (MD). 2nd edition. J.H. Lowinson, P. Ruiz (Eds.).
14. Weinshenker D., Schroeder J.P. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 2007, 32:1433-1451.
15. Wise R.A. Addictive drugs and brain stimulation reward. Annu Rev Neurosci 1996, 19:340.
16. Cunha-Oliveira T., Rego A.C. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev 2008, 58:192-208.
17. Gold M.S. The pharmacology of opioids. Principles of addiction medicine 1998, 131-136. American Society of Addiction Medicine, Inc, Maryland. 2nd edition. A.W. Graham, T.K. Schultz (Eds.).
18. Nestler E.J. Basic neurobiology of opiate addiction. New treatements for opiate dependence 1997, 286. Guilford Press, New York. S.M. Stine, T.R. Kosten (Eds.).
19. Strain E.C., Stitzer M.L. The treatment of opioid dependence 2006, Johns Hopkins Press, Baltimore (MD), p. 275-94.
20. Strain E.C. Pharmacology of buprenorphine. The treatment of opioid dependence 2006, Johns Hopkins Press, Baltimore (MD), p. 213-29.
21. Helm S., Trescot A.M., Colson J., et al. Opioid antagonists, partial agonists and agonists/antagonists: the role of office-based detoxification. Pain Physician 2008, 11:225-235.
22. Saidak Z., Blake-Palmer K., Hay D.L., et al. Differential activation of G-proteins by mu-opioid receptor agonists. Br J Pharmacol 2006, 147:671-680.
23. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. 4th edition.
24. Schuckit M.A., Segal D.S. Opioid drug abuse and dependence. Harrison's principles of internal medicine 2005, 2567-2570. McGraw Hill, New York (NY). 16th edition. D.L. Kaspar, E. Braunwald (Eds.).
25. O'Connor P.G., Kosten T.R. Management of opioid intoxication and withdrawal. Principles of addiction medicine 1998, 457-462. American Society of Addiction Medicine, Inc, Maryland. 2nd edition. A.W. Graham, T.K. Schultz (Eds.).
26. Amato L., Davoli M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2002, 3. CD003409.
27. Gossop M. Medically supervised withdrawal as stand-alone treatment. The treatment of opioid dependence 2006, 346-362. Johns Hopkins Press, Baltimore (MD). E.C. Strain, M.L. Stitzer (Eds.).
28. Nadelmann E., McNeely J. Doing methadone right. Public Interest 1996, 123:83-93.
29. O'Connor P.G., Kosten T.R. Rapid and ultrarapid opioid detoxification techniques. JAMA 1998, 279:229-234.
30. Kienbaum P., Scherbaum N., Thürauf N., et al. Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns. Crit Care Med 2000, 28:969-976.
31. Hamilton R.J., Olmedo R.E., Shah S., et al. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med 2002, 9:63-68.
32. Collins E.D., Kleber H.D., Whittington R.A., et al. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 2005, 294:903-913.
33. Gowing L., Ali R., White J. Opioid antagonists under heavy sedation or anesthesia for opioid withdrawal. Cochrane Database Syst Rev 2006, 1. CD002022.
34. Amato L., Minozzi S., Davoli M., et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2004, 4. CD005031.
35. Drug and treatment act of 2000. 21USC Available at:, Accessed February 10, 2010. http://buprenorphine.samhsa.gov/data.html.
36. Physician waiver qualifications Available at:, Accessed February 10, 2010. http://buprenorphine.samhsa.gov/waiver_qualifications.html.
37. Zhang Z., Friedmann P.D., Gerstein D.R. Does retention mater? Treatment duration and improvement in drug use. Addiction 2003, 98:673-678.
38. Mattick R.P., Breen C., Kimber J., et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003, 2. CD002209.
39. Kakko J., Svanborg K.D., Kreek M.J., et al. 1-year retention and social function after buprenorphine assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 2003, 361:662-668.
40. Fiellin D.A., O'Connor P.G., Chawarski M., et al. Methadone maintenance in primary care: a randomized controlled trial. JAMA 2001, 286:1724-1731.
41. Faggiano F., Vigna-Taglianti F., Versino E., et al. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003, 3. CD002208.
42. Gowing L.R., Farrell M., Bornemann R., et al. Brief report: methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006, 21:193-199.
43. Pearson E.C., Woosley R.L. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005, 14:747.
44. Chugh S.S., Socoteanu C., Reinier K., et al. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008, 121:66-72.
45. Krantz M.J., Martin J., Stimmel B., et al. QTc interval screening in methadone treatment. Ann Intern Med 2009, 150:387-393.
46. Mattick R.P., Kimber J., Breen C., et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003, 2. CD002207.
47. Barry D.T., Moore B.A., Pantalon M.V., et al. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med 2007, 22:242-249.
48. National Institute for Health and Clinical Excellence (NICE) Methadone and buprenorphine for the management of opioid dependence 2007, NICE, London.
49. Fischer G., Gombas W., Eder H., et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999, 94:1337-1344.
50. Schottenfeld R.S., Pakes J.R., Oliveto A., et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch gen psychiatry 1997, 54:713-720.
51. Luty J., O'Gara C., Sessay M. Is methadone too dangerous for opiate addiction?. BMJ 2005, 331:1352-1357.
52. Ling W., Compton P. Recent advances in the treatment of opiate addiction. Clin Neurosci Res 2005, 6:161-167.
53. Jones E.S., Moore B.A., Sindelar J.L., et al. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 2009, 99:132.
54. Stein M.D., Cioe P., Friedmann P.D. Buprenorphine retention in primary care. J gen intern med 2005, 20:1038-1041.
55. Amato L., Minozzi S., Davoli M., et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2008, 4. CD004147.
56. Christo G., Franey C. Drug users' spiritual beliefs, locus of control and the disease concepts in relation to Narcotics Anonymous attendance and six-month outcomes. Drug Alcohol Depend 1995, 38:51-56.
57. Christo G., Sutton S. Anxiety and self-esteem as a function of abstinence time among recovering addicts attending Narcotics Anonymous. Br J Clin Psychol 1994, 33:198-200.
58. Gossop M., Stewart D., Marsden J. Attendance at Narcotics Anonymous and Alcoholics Anonymous meetings, frequency of attendance and substance use outcomes after residential treatment for drug dependence: a 5-year follow-up study. Addiction 2008, 103(1):119-125.